Supplemental Financial Information (Tables)

6 Months Ended

Jun. 30, 2023

Supplemental Financial Statement Information [Abstract]

Schedule of Cash, Cash Equivalents and Restricted Cash

The reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheet to the totals shown within the condensed consolidated statement of cash flows is as follows (in thousands):

	As of June 30,
	2023		2022
Cash and cash equivalents	$	1,105,787	$	1,377,152
Restricted cash included in prepaid expenses and other current assets (1)		22,483		4,239
Restricted cash included in other non-current assets (1)		43,791		39,444
Total cash, cash equivalents and restricted cash	$	1,172,061	$	1,420,835

(1) Includes cash balances collateralizing letters of credit associated with the Company’s facility leases and a customer prepayment requiring segregation and restrictions in its use in accordance with the customer agreement.

Schedule of Inventory, Net

Inventory, net consisted of the following (in thousands):

	As of June 30,			As of December 31,
	2023			2022
Finished goods	$	4,435		$	6,556
Raw materials		905			1,590
Less: inventory reserve		(4,949	)		(3,782	)
Inventory, net	$	391		$	4,364

Summary of Property and Equipment Net

Property, plant, and equipment, net consisted of the following (in thousands):

	As of June 30,			As of December 31,
	2023			2022
Lab equipment	$	180,025		$	183,292
Leasehold improvements		136,197			125,307
Buildings and facilities		46,927			46,019
Construction in progress		19,831			23,426
Computer equipment and software		15,322			15,219
Furniture and fixtures		8,352			8,206
Land		6,060			6,060
Total property, plant, and equipment		412,714			407,529
Less: Accumulated depreciation and amortization		(118,470	)		(92,756	)
Property, plant, and equipment, net	$	294,244		$	314,773

Schedule of Capitalization

The following table presents the Company’s authorized, issued, and outstanding common stock as of the dates indicated (in thousands):

	Authorized		Issued		Outstanding
Common stock as of June 30, 2023:
Class A		10,500,000		1,595,167		1,478,611
Class B		4,500,000		378,273		356,093
Class C		800,000		120,000		120,000
		15,800,000		2,093,440		1,954,704
Common stock as of December 31, 2022:
Class A		10,500,000		1,448,234		1,337,499
Class B		4,500,000		383,649		354,477
Class C		800,000		200,000		200,000
		15,800,000		2,031,883		1,891,976

Schedule of Supplemental Cash Flow Information

The following table presents non-cash investing and financing activities (in thousands):

	Six Months Ended June 30,
	2023		2022 (as adjusted)*
Supplemental disclosure of non-cash investing and financing activities:
ROU Asset obtained in exchange for new operating lease liabilities upon adoption of ASC 842	$	—	$	147,744
ROU Asset obtained in exchange for new finance lease liabilities upon adoption of ASC 842		—		3,397
ROU Asset obtained in exchange for new operating lease liabilities		13,649		28,000
ROU Asset obtained in exchange for new finance lease liabilities		—		1,096
Purchases of property and equipment included in accounts payable and accrued expenses		2,324		6,741
Equity received in related parties		—		8,873
Convertible financial instruments received for Cell Engineering services		5,595		11,939
Equity securities and warrants received for Cell Engineering services		12,493		3,423
Settlement of contingent consideration - restricted stock		2,262		—
Common stock issued for business and asset acquisitions		3,581		17,015
Contingent consideration for business acquisition		—		12,306

* As adjusted to reflect the impact of the adoption of ASC 842 as of January 1, 2022. See Note 1 for a summary of the adjustments.